Abstract
The hemostatic effects of a new triphasic oral contraceptive combination containing ethinylestradiol and the new progestogen gestodene were compared with those of a triphasic combination of ethinylestradiol and levonorgestrel. A total of 19 women who did not use any kind of hormonal contraception 3 months prior to the study were recorded. The following parameters were measured: whole blood clotting time (WBCT), whole blood clot lysis time, fibrinogen, antithrombin III, factors V, VII and VIII. Blood samples were taken before treatment and in cycles 1, 3 and 6. A significant shortening of WBCT was observed in cycle 3 and 6 in both groups and also in cycle 1 in the gestodene group. This may indicate an increased sensitivity for activation of platelets, since the assay appears to be quite sensitive to this process. In the other parameters tested there were no significant changes except for a slight increase in plasma fibrinogen in cycle 1 in the gestodene group.
Citations
Jan 1, 1995·Contraception·A F SchlitE Lavenne
May 1, 1996·Maturitas·H Kuhl
Dec 5, 2000·Contraception·U H Winkler
Oct 13, 1999·Contraception
Jan 10, 2002·Fertility and Sterility·Marcelle I Cedars
Nov 1, 1992·American Journal of Obstetrics and Gynecology·M NotelovitzF Y Khan
May 1, 1994·American Journal of Obstetrics and Gynecology·D Shoupe
Jul 1, 1991·Contraception·R W Rebar, K Zeserson
Mar 7, 1998·Baillière's Clinical Obstetrics and Gynaecology·L A Norris, J Bonnar
Sep 30, 1998·American Journal of Obstetrics and Gynecology·U H Winkler
Jan 26, 2012·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Kyle R BrandyAfshin A Divani
Sep 21, 2000·Cephalalgia : an International Journal of Headache·J Conard, M M Samama
Dec 1, 1994·British Journal of Obstetrics and Gynaecology·G E Robinson
Mar 9, 2006·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·José Mendes AldrighiLuis Bahamondes
May 1, 1992·Progress in Cardiovascular Diseases·J FareedR Pifarre